Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123059392 | 12305939 | 2 | F | 20160822 | 20160426 | 20160901 | EXP | JP-MYLANLABS-2016M1016802 | MYLAN | NARIMATSU A.. A CASE OF OVARIAN CARCINOSARCOMA SUCCESSFULLY TREATED BY PACLITAXEL AND CARBOPLATIN CHEMOTHERAPY.. OBSTET. GYNECOL. (TOKYO). 2016;83(4):455-460 | 0.00 | Y | 0.00000 | 20160901 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123059392 | 12305939 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous drip | AUC 5 | U | U | 91063 | INJECTION | |||||||
| 123059392 | 12305939 | 2 | SS | TAXOL | PACLITAXEL | 1 | Intravenous drip | 175 MG/M2, QD | U | U | 0 | 175 | MG/M**2 | INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123059392 | 12305939 | 1 | Ovarian cancer stage IV |
| 123059392 | 12305939 | 2 | Ovarian cancer stage IV |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 123059392 | 12305939 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123059392 | 12305939 | Alopecia | |
| 123059392 | 12305939 | Gastrointestinal disorder | |
| 123059392 | 12305939 | Myalgia | |
| 123059392 | 12305939 | Neutrophil count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |